id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-E-2656-0007,FDA,FDA-2015-E-2656,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-07-29T04:00:00Z,2018,7,2018-07-29T04:00:00Z,,2018-07-29T17:01:46Z,,0,0,090000648357d7e3
FDA-2015-E-2656-0006,FDA,FDA-2015-E-2656,Determination of Regulatory Review Period for Purposes of Patent Extension; ZYKADIA,Notice,Determinations,2017-12-26T05:00:00Z,2017,12,2017-12-26T05:00:00Z,2018-02-27T04:59:59Z,2017-12-26T16:07:16Z,2017-27745,0,0,0900006482d732f2
FDA-2015-E-2656-0005,FDA,FDA-2015-E-2656,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-06-05T04:00:00Z,2017,6,2017-06-05T04:00:00Z,,2017-06-05T19:45:22Z,,0,0,0900006482692a82
FDA-2015-E-2656-0004,FDA,FDA-2015-E-2656,Letter from U.S. Patent and Trademark Office to CDER,Other,Letter(s),2016-11-23T05:00:00Z,2016,11,2016-11-23T05:00:00Z,,2016-11-23T12:57:37Z,,0,0,09000064823b943a
FDA-2015-E-2656-0003,FDA,FDA-2015-E-2656,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-10-20T04:00:00Z,2015,10,2015-10-20T04:00:00Z,,2015-10-20T16:28:19Z,,0,0,0900006481ccfe49
FDA-2015-E-2656-0002,FDA,FDA-2015-E-2656,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2015-07-27T04:00:00Z,2015,7,2015-07-27T04:00:00Z,,2015-07-27T11:58:58Z,,0,0,0900006481ba56f8
FDA-2015-E-2656-0001,FDA,FDA-2015-E-2656,Patent Extension Application from NOVARTIC PHARMACEUTICAL CORP (on behalf of IRM LLC),Other,Application,2015-07-27T04:00:00Z,2015,7,2015-07-27T04:00:00Z,,2015-07-27T11:58:52Z,,0,0,0900006481ba56fa